1. Home
  2. CTMX vs BLMN Comparison

CTMX vs BLMN Comparison

Compare CTMX & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • BLMN
  • Stock Information
  • Founded
  • CTMX 2008
  • BLMN 1988
  • Country
  • CTMX United States
  • BLMN United States
  • Employees
  • CTMX N/A
  • BLMN N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • BLMN Restaurants
  • Sector
  • CTMX Health Care
  • BLMN Consumer Discretionary
  • Exchange
  • CTMX Nasdaq
  • BLMN Nasdaq
  • Market Cap
  • CTMX 596.2M
  • BLMN 625.3M
  • IPO Year
  • CTMX 2015
  • BLMN 2012
  • Fundamental
  • Price
  • CTMX $3.32
  • BLMN $7.51
  • Analyst Decision
  • CTMX Strong Buy
  • BLMN Hold
  • Analyst Count
  • CTMX 5
  • BLMN 9
  • Target Price
  • CTMX $5.80
  • BLMN $9.25
  • AVG Volume (30 Days)
  • CTMX 3.0M
  • BLMN 1.8M
  • Earning Date
  • CTMX 11-07-2025
  • BLMN 11-06-2025
  • Dividend Yield
  • CTMX N/A
  • BLMN 7.99%
  • EPS Growth
  • CTMX 263.20
  • BLMN N/A
  • EPS
  • CTMX 0.49
  • BLMN N/A
  • Revenue
  • CTMX $141,100,000.00
  • BLMN $3,933,993,000.00
  • Revenue This Year
  • CTMX N/A
  • BLMN $1.43
  • Revenue Next Year
  • CTMX N/A
  • BLMN $1.40
  • P/E Ratio
  • CTMX $6.79
  • BLMN N/A
  • Revenue Growth
  • CTMX 18.01
  • BLMN 2.47
  • 52 Week Low
  • CTMX $0.40
  • BLMN $6.09
  • 52 Week High
  • CTMX $3.91
  • BLMN $17.57
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 55.87
  • BLMN 50.46
  • Support Level
  • CTMX $3.21
  • BLMN $7.56
  • Resistance Level
  • CTMX $3.91
  • BLMN $8.17
  • Average True Range (ATR)
  • CTMX 0.26
  • BLMN 0.35
  • MACD
  • CTMX -0.06
  • BLMN 0.02
  • Stochastic Oscillator
  • CTMX 30.59
  • BLMN 50.00

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

Share on Social Networks: